Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis

Osteoarthritis Clinical Trial

Official title:

A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02183064
• Other study ID #: 107.210
• Status: Completed
• Phase: Phase 3
• First received: July 4, 2014
• Last updated: July 7, 2014
• Start date: October 1998

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Study to compare the percentage of treatment successes or failures in patients randomized to meloxicam 7.5 mg vs. usual care prescription NSAIDs. Additionally, health care utilization, efficacy and safety of patients in a managed healthcare setting with osteoarthritis (OA) of the hip, knee, hand or spine will be assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1309
• Est. primary completion date: November 2000
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and females over the age of 18

• The patient, if female and of reproductive potential (i.e. neither surgically sterilized nor post-menopausal), must be practicing adequate contraception (e.g. intrauterine device, contraceptive pills, Depo-Provera, or implant or double barrier device) for at least three months prior to and for the duration of their trial participation and must have a negative pregnancy test at screening. Abstinence is not considered to be an acceptable method of contraception. (It should be noted that NSAIDs might interfere with the effectiveness of intrauterine devices)

• The patient must have a documented diagnosis of at least one of the following:

• Osteoarthritis of the hip

• Osteoarthritis of the knee

• Osteoarthritis of the hand or

• Osteoarthritis of the spine - Patients must have radiographic confirmation of the diagnosis

• The patient is willing to change or requires a change in current prescription NSAID therapy or requires initiation of prescription NSAID therapy for treatment of OA of the hip, knee, hand or spine

• The patient intends to remain a member of their present Managed Care Organization (MCO) for the duration of the trial

• The patient is willing to comply with instructions and to provide written informed consent

Exclusion Criteria:

• The patient has a known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDS (prescription or over-the-counter)

• The patient has received an investigational drug or used an investigational device within 30 days prior to entering the trial

• In the opinion of the investigator the patient has any disease or condition that may result in altered absorption, excess accumulation or impaired metabolism or excretion of the trial medication

• The patient has a history of recurrent peptic ulcer or history (within the past 6 months) of gastrointestinal perforation, peptic ulceration documented by endoscopy or radiography, symptomatic hiatal hernia requiring daily treatment or any history of a gastrointestinal tract hemorrhage, except simple hemorrhoidal bleeding

• The patient is currently on coumadin or might be placed on coumadin during the course of the clinical trial

• Patients with dementia, i.e. incapable of following directions or complying with the study protocol

• Patients with co-existing rheumatological disorders including rheumatoid arthritis

• The patient has previously participated in this trial

• Patients with coexisting fibromyalgia or ankylosing spondylitis

• Patient is pregnant or lactating

• Patient has severe hepatic failure

• Patient has non-dialysed renal failure

• Patient has history of GI bleed within the past 6 months

• Patient has history of cerebrovascular bleeding or other bleeding disorders

• Patient is receiving concomitant lithium, heparin or ticlopidine therapy

• Patient has a history of leukopenia (White Blood Cell count < 3500/mm³)

• The patient has a history of platelet count below the lower limit of normal or has a documented abnormal prothrombin time (PT) or partial thromboplastin time (PTT)

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis

Intervention

Drug:
• Meloxicam

• NSAID

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of treatment successes and failures in patients randomized to meloxicam 7.5 mg vs.usual care prescription NSAIDs		up to 6 month	No
Secondary	Investigator's Global Assessment of Disease Activity (Likert)		Screening (Day 0), after six month (Day 180)	No
Secondary	Patient's overall Assessment of pain over the past week on a visual analogue scale (VAS)		Day 0, 30, 60, 90, 120, 150, 180	No
Secondary	Patient's Assessment of Health Status (VAS)		Day 0, 30, 60, 90, 120, 150, 180	No
Secondary	Patient's Assessment of Satisfaction of Health		Day 0, 30, 60, 90, 120, 150, 180	No
Secondary	Utility Index (VAS)		Day 0, 30, 60, 90, 120, 150, 180	No
Secondary	Western Ontario and Mc Master University Osteoarthritis Index (WOMAC)		Day 0, 30, 60, 90, 120, 150, 180	No
Secondary	Medication Compliance		Day 30, day 180	No
Secondary	Disability Index		Screening (Day 0), after six month (Day 180)	No
Secondary	Permanent Discontinuation of Study Medication related to lack of efficacy		up to day 180	No
Secondary	Incidence and intensity of adverse events		from day 30 until day 180	No
Secondary	Permanent Discontinuation of Study Medication related to adverse event		from day 30 until day 180	No

External Links

•   Link